Stock Analysis
Cigna Corporation (CI) Stock Analysis
Cigna Corporation (CI) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Cigna Corporation (CI) currently has an AIQ Score of 56/100, indicating a neutral setup. Value is the strongest factor at 72/100. Quality is the weakest current factor at 39/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
CI at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $282.52 |
| AIQ Score | 56/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Buy |
| Market Cap | $74.8B |
| P/E Ratio | 9.16 |
| Forward P/E | — |
| EPS | $6.29 |
| Revenue TTM | $71.67B |
| Dividend Yield | 0.01% |
| Beta | 0.32 |
| Volume | 1.2M |
| 52-week range | $239.51-$315.47 |
| RSI 14 | 59.57 |
| 50-Day SMA | $283.45 |
| 200-Day SMA | $279.58 |
| Analyst Price Target | $337.67 |
| Next Earnings | Oct 29, 2026 |
CI
OverviewCI Stock Analysis Summary
Cigna Corporation (CI) currently has an AIQ Score of 56/100, indicating a neutral setup. Value is the strongest factor at 72/100. Quality is the weakest current factor at 39/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, CI has AIQ Score of 56/100 with Value base of 72/100 and fading Quality at 39/100. Wait for component alignment before adding exposure.
Value (72/100) leads while Quality (39/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -1.31% stock move · CI classified in Medical - Healthcare Plans.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is CI Bullish or Bearish Right Now?
CI currently has a neutral overall setup. Value is the strongest factor at 72/100, while Quality is weakest at 39/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 60/100.
- - Analyst target implies +19.52% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (24 vs 11).
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
CI's Technical Analysis Consensus is currently Buy, with 24 buy, 10 neutral, and 11 sell votes. CI's 14-day RSI is 59.57, which places the stock in a constructive momentum range. CI's beta is 0.32, indicating lower market sensitivity than the broad market.
What Changed in CI?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the CI Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
CI Decision Framework
Public evidence layers, setup checks, and risk context for Cigna Corporation.
Cigna Corporation (CI) Stock Analysis
Cigna Corporation has an AIQ Score of 56/100 in a Neutral regime. Value is strongest at 72/100. Beta is 0.32, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | CI is in a Neutral AIQ regime with score 56/100. |
| Signal Conflict | The primary conflict is that value leads at 72/100 while quality lags at 39/100. |
| Factor Evidence | Momentum 60/100 · Value 72/100 · Quality 39/100 · Risk 52/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Value is the strongest factor at 72/100.
Momentum is 60/100 and RSI (14) is 59.6.
CI is in a Neutral regime at 56/100.
Risk factor is 52/100 with beta 0.32 and annual volatility 32.52%.
Current conflict: value leads at 72/100 while quality lags at 39/100.
CI Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
CI Fundamentals
CI valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
CI Technical Analysis
CI technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
CI Stock Catalysts
Track CI earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
CI Dividend Analysis
CI dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
CI Financial Data
CI revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
CI Risk Analysis
CI volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
CI Stock News
CI stock news, market tone, recent headlines, and catalyst context.
CI vs Healthcare Services / Managed Care Peers
Current peer cohort: CI · CLOV · CNC · COR · CVS. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| CI Current stock | 56/100 | 72/100 | 60/100 | 52/100 | -0.18 | 32.52% | Current |
| CLOV Clover Health | 41/100 | 42/100 | 47/100 | 37/100 | 0.96 | 67.06% | CI vs CLOV |
| CNC Centene | 51/100 | 53/100 | 73/100 | 58/100 | 1.91 | 48.93% | CI vs CNC |
| COR Cencora | 59/100 | 62/100 | 80/100 | 55/100 | 0.43 | 31.52% | CI vs COR |
| CVS CVS Health | 52/100 | 70/100 | 59/100 | 53/100 | 0.91 | 31.19% | CI vs CVS |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 4, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 5, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching CI
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for CI
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
CI Stock FAQ
What is CI stock price today?
Cigna Corporation's current stock price is $282.52. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is CI bullish or bearish right now?
CI's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is CI's market cap?
CI's market cap is $74.8B based on the latest completed market-close snapshot from Sep 4, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is CI's current P/E ratio?
CI's current P/E ratio is 9.16 based on the latest completed market-close snapshot from Sep 4, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is CI's RSI?
CI's 14-day RSI is 59.57 based on the latest completed market-close snapshot from Sep 4, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is CI above its 50-day and 200-day moving averages?
CI is -0.33% from its 50-day SMA and 1.05% from its 200-day SMA based on the latest completed market-close snapshot from Sep 4, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is CI's next earnings date?
CI's next earnings date is currently listed as Oct 29, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does CI pay a dividend?
CI's dividend yield is 0.01% based on the latest completed market-close snapshot from Sep 4, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.